Navigation Links
AtheroNova Releases 2011 Financial Results
Date:3/21/2012

IRVINE, Calif., March 21, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has released financial results for fiscal 2011.  As a development stage company, no revenues were recognized in the twelve months ended December 31, 2011.  Losses from operations were $2,560,235 for 2011 compared to $2,679,435 in 2010.  Net income was $4,263,286, or $0.17 per basic share ($0.15 diluted), in the year ended December 31, 2011 compared to a loss of $15,656,852, or ($0.70) per basic and diluted share, for the year ended December 31, 2010.

"This past year was a period of clear progress as we significantly enhanced our management team and scientific advisory board," said AtheroNova CEO Thomas W. Gardner. "The regression and prevention of atherosclerosis represents a multi-billion dollar market. This considerable market size and identifiable near term milestones positions us for a significant growth opportunity. We continue to remain on track with our development activities and 2012 will be a year of substantial evolution. We continue to advance the AHRO-001 product, as we recently announced the first shipment to our R&D partner, CardioNova; a clear milestone as we prepare for our upcoming human clinical trials. As CardioNova commences toxicology studies conducted for Russian regulatory purposes, we expect our progress to accelerate in the coming months as we achieve additional development milestones."

As the company continues to make progress it is important that its stakeholders are aware of the upcoming key milestones and highlights.

Key Near-Term Milestones

  • Q2'12 - Publication of pre-clinical studies anticipated
  • Q2'12 - IND filing
  • Q3'12 - Initiating Phase I clinical study
  • Q3'12 - FDA meeting pre Phase II
  • Q4'12 - Initiating Phase II Clinical study


  • '/>"/>
    SOURCE AtheroNova Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
    2. AtheroNova Announces a New Board Member
    3. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
    4. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
    5. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
    6. eCareSoft Releases eCS Cirrus™
    7. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
    8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
    9. Ion Torrent Gets Better Faster With 4th Qtr New Product Releases
    10. ICGC Releases New Genomic Data on Cancer Ahead of Schedule
    11. ACTE Releases Paper on How Career, Technical Student Organizations Expand Career Readiness for Students
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
    (Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 ... sponsoring of the winners of the 2015 BeHEARD science ... Institute that offers rare disease researchers, access to the ... will use its drug repositioning and pathway analytics capability ... at Wylder Nation Foundation in the study of Niemann-Pick ...
    (Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
    (Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
    Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
    ... China , May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, ... and distributor in China of glucose and starch ... that it issued financial results for the third quarter of ... before the opening of the stock,market in USA on ...
    ... ,, PLEASANTON, Calif. , May 17 TriReme ... for an expanded matrix of sizes for its GliderXtreme™ PTA balloon ... lesions in the peripheral vasculature in balloon diameters from 2.0 – ... , , ...
    ... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that it ... to prevent attacks of hereditary angioedema (HAE), with West Pharmaceutical Services, ... simple-to-use reconstitution device and accompanying training materials will be widely available ... , , ...
    Cached Biology Technology:Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call 2Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call 3TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 3ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 4ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 5
    (Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
    (Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
    (Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
    Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
    ... gone underground to get the most top secret information ... in his experimental orchards, and it is sort of ... is part of a national specialty crop research project ... Texas AgriLife Research horticultural scientist, will focus on pecans ...
    ... causes temperatures to increase in Hawaii,s mountains, deadly ... the mountains, invading most of the last disease-free ... and remarkable birds. A just-published U.S. ... a forthcoming "disease invasion" by examining the present ...
    ... around the world will convene at the University of ... from the most ambitious effort ever undertaken to measure ... they contribute in the near term to the dramatic ... two-year international field campaign known as POLARCAT was conducted ...
    Cached Biology News:Getting to the root of science in a nutty way 2Jeepers creepers: Climate change threatens endangered honeycreepers 2Jeepers creepers: Climate change threatens endangered honeycreepers 3Spring agricultural fires have large impact on melting Arctic 2Spring agricultural fires have large impact on melting Arctic 3
    V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
    Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
    ...
    ... Building on the ease of use and flexibility of ... Biosciences introduces the BDTM LSR II. The BD ... before in a benchtop analyzer. Free up your ... a UV laser to the BD LSR II. The ...
    Biology Products: